



CDISC Standards: Now and to Come

Wayne Kubick

Chief Technology Officer, CDISC

Strength through Collaboration

Keynote

From Wikipedia, the free encyclopedia


“A keynote is a talk that **establishes the main underlying theme**. The keynote lays the framework for the following programme of events or convention agenda.

Keynote speakers are often selected to raise interest in a particular event, and draw attendees to attend that program. Selecting a keynote speaker who is well known for his or her expertise in a particular field, or who has wide name recognition due to other accomplishments, **will probably raise enthusiasm** among prospective attendees for a meeting or conference.

The term *key note* comes from the practice of a *cappella*, often barbershop singers playing a note before singing. The note played determines the key in which the song will be performed.”

“See how to apply SAS specifically to the challenges of the pharmaceutical and healthcare industry, understand issues related to FDA regulatory compliance, and explore emerging industry standards like CDISC, SDTM, and ADaM.”

CDISC Standards Now




"First things first, but not necessarily in that order."

-- Dr. Who


The Clinical Data Interchange Standards Consortium

- Global, open, multi-disciplinary, vendor-neutral, non-profit standards developing organization (SDO)
- 501(c)(3) charitable non-profit Founded 1997, incorporated 2000
- Member-supported (>300 academia, biopharma, service providers)
- Associations with ISO TC 215 (Liaison A), HL7, Joint Initiative Council
- Coordinating Committees in Europe, Asia
 - Participants from > 90
- Standards freely available.



The CDISC Vision: Informing patient care and safety through higher quality medical research

The CDISC Standards Guide



1-Click Standards

<u>Pain v1</u>	Provisional	August 7, 2012
<u>Parkinson's Disease</u>	Provisional	December 18, 2012
<u>Polycystic Kidney Disease</u>	Review Closed	November 30, 2012
<u>Tuberculosis v1</u>	Provisional	June 29, 2012
<u>Virology</u>	Provisional	December 6, 2012

Questionnaire	Version	Short Name (QSCAT)	Permission	Release Date
<u>Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)</u>	V1.0	ADAS-COG	Granted	January 26, 2012
<u>Brief Pain Inventory-Interference Scale - Short Form (BPI-I)</u>	V1.0	BPI SHORT FORM	Granted	
<u>Brief Pain Inventory-Interference Scale (BPI-I)</u>	V1.0	BPI	Granted	August 7, 2012
<u>Brief Psychiatric Rating Scale-Anchored (BPRS-A)</u>	V1.0	BPRS-A	Public Domain	January 29, 2013
<u>Clinical Global Impression (CGI)</u>	V1.0	CGI	Public Domain	August 7, 2012
<u>Columbia Suicide Severity Rating Scale - Baseline</u>	V1.0	C-SSRS BASELINE	Granted	August 7, 2012

Key Technical Initiatives for 2013

- Communicate updated tech plan, roadmap, status
- Improve integration and cooperation across teams – host Intra-Changes
- Make SHARE real and sustainable
- Improve online collaboration tools for standards teams
- Improve involvement of global volunteers
- Still more transparency:
 - Publish new charters
 - Maintain schedule of milestones
 - Improve project tracking info
- Improve processes
 - Rollout new standards process, tools, training
 - Expand Stds Review Council
 - Appreciate volunteers
- Coordinated new versions of foundational standards (SDTM)
- Make CFAST succeed


The CDISC Standards Review Council

- Reviews all standards prior to posting for comment or provisional or final use
- Verifies quality, completeness, and harmonious consistency with existing standards
- Provide input and advice on new initiatives or on issues escalated from teams as requested
- Meets biweekly; Chaired by CTO


Public Comment Tracker – CDISC Needs You!

Comment Title	Comment	Document Being Commented On	Document Section	Comment Category	Current State	Comment Author	Assigned To - Team R
NUMLIV instead of NUJMLIV	page 9, RD.XPT, Row 2, RDTSTCD: NUMLIV instead of NUJMLIV	XXX Comment Period Closed - SDTM IG 003 - RD Reproductive Details v3.1.4 Draft	6.3.14.2	Select or Blank	Closed	Lorenz Dolanski-Aghamanoukjan	
Request for Additional Example	Would it be possible to add an additional example of how to collect data in EX domain for combination drugs. For example, 1 tablet contains 3 drugs: Drug A (10mg), Drug B(50mg) Drug C(30mg). Since this is a combination I am not sure what to put in EXDOSE.	XXX Comment Period Closed - SDTM IG 001 - EX and EC ExposureDomains v3.1.4 Draft		Suggestion	Select or Blank	David Ramage	
comments to EX and EC doc	<p>1. EXMOOD has controlled terminology (MOOD). The most recent CT does not contain CT for this, so want to make sure that this will be released in conjunction with the 3.1.4 release?</p> <p>2. Is it intentional that BRIDG mapping is missing for EXDIR and EXPORTOT?</p> <p>3. Same question as #1 for EXPORTOT (PORTOT). EXMETHOD (MTHADM), etc.</p> <p>4. font size inconsistencies on page 20</p> <p>5. Page 24, second paragraph of Example 2, should say 'ABC123-0201' instead of 'ABC123-1001' to be consistent</p>	XXX Comment Period Closed - SDTM IG 001 - EX and EC ExposureDomains v3.1.4 Draft		Select or Blank	Select or Blank	kris ilano	

Proposed Online Course Release Schedule




CDISC Standards to Come




"If we don't change direction soon,
we'll end up where we're going."

-- Professor Irwin Corey


2013 CDISC Technical Plan – Foundational Standards



CDISC Technical Roadmap



Data Transparency & Accessibility



"Somebody has to do something, and it's just incredibly pathetic that it has to be us."

-- Jerry Garcia



John Wilbanks: Let's pool our medical data | Video on TED.com

www.ted.com/talks/john_wilbanks_let_s_pool_our_medical_data.html

GoToMeeting iGoogle Apple Yahoo! Google Maps YouTube Wikipedia News Popular

World P... iGoogle CDISC... Yahoo! Home 5 Steps... John W...

TED Ideas worth spreading

Talks	TED Conferences	TED Conversations
Speakers	TEDx Events	TED Community
Playlists NEW	TED Prize	TED-Ed NEW
Translations	TED Fellows	

Search

New TED Talks are released every weekday. Be the first to know!

Enter your email for TED updates Daily Weekly Fol

TALKS

John Wilbanks: Let's pool our medical data

FILMED JUN 2012 • POSTED OCT 2012 • TEDGlobal 2012



282,988 Views ?

When you're getting medical testing, privacy is important. What researchers can see and what if your medical data could be used by anyone seeking to test a hypothesis? Wilbanks wonders if the desire for open research, and if open research lead to a wave of health care innovation.

Imagine the discoveries that could be made from a pool of freely available health data. Wilbanks is working to build it.

Embed Download Favorite Rate Show transcript

Share More Tweet

TED CONVERSATIONS

Got an idea, question, or debate inspired by this talk? [Start a TED Conversation.](#)

TED GLOBAL 2013
WELCOME TO THE

RELATED PLAYLISTS **NEW**

 **The joy**
Curated by
What can pleasure talks from writers celebrate



Access to clinical-trial data and transparency **Workshop report**

An agency of the European Union



Agency moves towards proactive publication of clinical-trial data

Across Europe, regulators and governments are turning their attention towards a key healthcare issue – the transparency of clinical trials, in particular the release and withholding of data.



- Single, trusted, authoritative source for CDISC data standards
- Concepts, metadata, collections, relationships, value sets across the full spectrum of CDISC content
- Links research to healthcare concepts to support interoperability
- Aligned with NCI Semantic Systems

BRIDG, ISO21090





Protocol, CDASH



SDTM, ADaM



Terminologies




Facilitates Data Exchange

- Access to data standards
- Source to target mapping & traceability
- Transformation logic

Adapted from Source by Sue Dubman, Sanofi-Aventis

CDISC, CFAST & Therapeutic Area Standards



"The art of medicine consists in amusing the patient while nature cures the disease."


--Voltaire



THE
DEADLIEST
DISEASES
COULD BE PREVENTED
OR CURED BY
THIS WEBSITE



PKD Clinical Use Case



CAMD Data Repository for Alzheimer's Disease

CRITICAL PATH INSTITUTE

C-PATH ONLINE DATA REPOSITORY

CODR Version: v0.14.3 Database Version: 7.1

Report Library Data Access Batches Resources Admin

Saved Reports New Report Manage Report Categories Manage Data Sources

Batch Job Status Batch job not currently running | Run Job



The CAMD database is currently composed of the placebo arm data from clinical trials conducted by the member companies. These trials include drugs on the market or at different stages of development including termination.



- CAMD Goal – identify biomarkers to ID patients very early in their disease
- Using CDISC standards, remapped and pooled data from 22 clinical trials; >6,000 patients
- Database open to qualified researchers; currently >200 in 35 countries



FDA PDUFA V goals 2013-2017

Clinical Terminology Standards (Section XII E pg 28):

Using a public process that allows for stakeholder input, FDA shall develop standardized clinical data terminology through



FDA has defined specific goals for development and use of data standards

of completing clinical data terminology and detailed implementation guides by FY 2017.

<http://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm270412.pdf>

Coalition For Accelerating Standards & Therapies



- CFAST is an initiative to accelerate clinical research and medical product development by creating and maintaining data standards, tools and methods for conducting research in therapeutic areas that are important to public health
- With the enactment of FDASIA/PDUFA V, FDA recognized the opportunity to work with CFAST, along with TransCelerate Biopharma and the pharmaceutical industry, to develop therapeutic area data standards.


Current Status: Therapeutic data standards

Released Standards 2011-2012	Work in Progress	Planned for 2013
Alzheimer's Disease	Asthma	Traumatic Brain Injury
Pain	Alzheimer's v 1.1	Oncology
Tuberculosis	Multiple Sclerosis	Schizophrenia
Virology	Cardiovascular	Virology v2 – Hepatitis C
Parkinson's Disease	Diabetes	
Polycystic Kidney Disease		

Therapeutic Area Standards: Baseline Content

- Mindmap/model of disease area clinical concepts
- Essential core data elements with definitions, data types (simple & ISO 21090), BRIDG and SDTM mappings
- SDTM domains and examples
- Minimum value sets (code lists) with definitions and c-codes
- User/Implementation Guide with permissions statement
- Standard CDASH CRFs with SDTM annotations, as appropriate
- Ideally, ADaM Analysis model examples (e.g., ADSL)
- Possibly study design models, SEND examples, etc.


Developing CDISC Standards



"Mustard's no good without roast beef."

-- Chico Marx

A New Process




Asthma User Guide Example

5 Symptom Assessment


Asthma symptoms can present in various forms. The most common symptoms of asthma are wheezing, cough, breathlessness, chest tightness and night time awakenings. These symptoms are often assessed using validated instruments as described in the section on Patient Reported Outcomes. They may also be described using sponsor-defined Likert scales or visual analog scales.

Symptom	Closest MedDRA LLT	MedDRA Preferred Term
Wheezing	Wheezing	Wheezing
Cough	Cough	Cough
Breathlessness	Breathlessness	Dyspnoea
Chest tightness	Chest tightness	Chest discomfort
Nighttime awakening	Nocturnal awakening	Middle Insomnia

Data typically collected for asthma symptoms include the focal time period and the subject's rating of symptom severity or symptom impact. Occurrence is sometimes combined with severity or impact by including a value of "None" or "Absent" in the set of severity or impact responses.



SHARE Business Template Example for Vital Signs



- Helps focus user attention on content rather than model details
- Domain friendly – Do not have to know the BRIDG model
- Do not have to understand the ISO 21090 data types

Target Timelines Under New Process


Stage 0	Stage 1	Stage 2	Stage 3		
Scoping, Inputs, Planning	Concept Definition and Modeling	Standards Development (Metadata, Terminology, User Guide, Examples)	Internal Review	Public Review	Publication
Months <1-2	Months 2-4	Months 3-6	Months 6-10+		

CDISC Standards and FDA

*the signal and the
and the noise and
the noise and the
noise and the no
why so many and
predictions fail—
but some don't th
and the noise and
the noise and the
nate silver noise
noise and the no*

“It’s not what you *don’t* know that gets you in trouble. It’s what you *think* you know that just ain’t so.”

--Mark Twain



FDA Messages on Standards



- “The World is Round”
 - Clinical data are not flat and cannot be exchanged using flat two-dimensional files without significant loss of meaning
- FDA is transitioning to a “round view of the world” of clinical research
 - CDISC-HL7 standard will get us there
- SDTM is here to stay
 - Will transition from a standard submission format to a standard view of data in support of simple analyses (e.g. distribution, means, etc.)
- But Flat Files Don’t Inherently Capture the Tree Structure, which is itself important to understand the data
 - **Better approach: data model that inherently captures relationships at the point of collection and can transmit them.**

Source: Armando Oliva, FDA



SEARCH

Most Popular Searches

- [Home](#)
- [Food](#)
- [Drugs](#)
- [Medical Devices](#)
- [Radiation-Emitting Products](#)
- [Vaccines, Blood & Biologics](#)
- [Animal & Veterinary](#)
- [Cosmetics](#)
- [Tobacco Products](#)

Drugs

Home > Drugs > Development & Approval Process (Drugs) > Forms & Submission Requirements



Development & Approval Process (Drugs)

[Forms & Submission Requirements](#)

[Electronic Submissions to CDER](#)

[CDER Data Standards Program](#)

[Electronic Common Technical Document \(eCTD\)](#)

[Electronic Regulatory Review](#)

[Electronic Regulatory Submissions and Review Helpful Links](#)

[Electronic Submissions Presentations](#)

[Study Data Standards for Submission to CDER](#)

[Data Standards Manual \(monographs\)](#)


CDER Study Data Standards Research and Development

Study Data Exchange Standards R&D

- Over the past few years, CDER has increased its support for standardized study data submissions using CDISC standards, and will continue to do so in the future.
- Currently, CDER supports the submission of CDISC content using SAS Transport File version 5.
- As adoption of CDISC standards increases in CDER and throughout the regulated industry, we recognize the inherent limitations of using SAS transport files for data exchange. These include:
 - 8-character limitation for variable names
 - 40-character limitation for labels for variables
 - 200-character limitation for character fields
 - Flat, two-dimensional file structure for what we now recognize is multi-relational, multi-dimensional data
- Within our overall drug review modernization efforts, CDER recognizes the need to identify a pathway for moving away from SAS Transport to a more modern, robust, and flexible transport mechanism for CDISC content and certain other study data currently submitted in PDF format.
- Ongoing work on the CDISC-HL7 Study Data Standards project indicates that HL7 version 3 xml may be a promising solution for the exchange of study data. The potential benefits include:
 - No variable or data field size limitations
 - More multi-relational representation of the data
 - Ability to transport more content (e.g. unstructured text such as patient narrative information)
 - Improved harmonization with other HL7 v.3 data standards for healthcare and regulatory information (e.g. Individual Case Safety Report, Regulated Product Submission, Clinical Trials Registry and Results, Clinical Document Architecture)
 - Improved interoperability with healthcare and other regulatory information systems
- In parallel with our ongoing robust CDISC implementation efforts, CDER intends to conduct a Proof of Concept (PoC) and test in a measured, iterative, and incremental fashion the use of HL7 v.3 xml as a possible exchange method for certain use cases. Testing will proceed incrementally for the following use cases:
 - Submission of Patient Narrative and Clinical Investigator Qualification Information (e.g. FDA Form 1572)
 - Submission of Structured Protocol Information
 - Submission of Subject Data
- Testing will include an opportunity for interested stakeholders to participate in an open and transparent manner.
- Careful evaluation of the test and an assessment of the costs, benefits and impacts of potential migration to a new exchange method—on both FDA and regulated industry— will be conducted to inform possible next steps. A determination of whether and how to proceed will be based on that thorough evaluation of the pilots and proposals for further development or adoption.
- CDER is committed to working throughout the standards development and implementation processes with




Janus CTR



CFAST TA SC Meeting – 21 March 2013

Draft FDA Standards Development Process



Source: Mary Ann Slack, FDA

STUDY QUALITY REPORT: 048

Evaluation Date: 17-Sep-2012 10:29 PM


Dashboard Profiles Domains Issues Rules History

[Export to Excel](#)

Quality Dimension: All

Profile	Score	Pass/Fail	Domains	Issues	Failures	Errors	Warnings	Notices
Analysis Support								
FDA Demographics Panel	99	Pass	3	2	2	0	1	1
FDA Adverse Events Panel	0	Fail	3	8	55,414	1	55,410	3
FDA Disposition Panel	0	Fail	3	3	20,274	20,272	0	2
FDA Exposure Panel	0	Fail	2	2	3	1	0	2
FDA Liver Function Panel	0	Fail	3	12	29,729	25,656	4,072	1
FDA Oncology Adverse Events Panel	0	Fail	3	8	55,414	1	55,410	3
FDA Overall Survival Panel	0	Fail	6	10	27,590	2	27,587	1
General Quality								
OpenCDISC SDTM v3.1.2 Data Quality	49	Pass	31	60	845,972	352,719	493,252	1
Metadata								
OpenCDISC Study Metadata	100	Pass	31	0	0	0	0	0
Standards Compliance								
OpenCDISC Define.xml v1.0 Compliance	100	Pass	1	1	30	0	30	0
OpenCDISC SDTM v3.1.2 Compliance	90	Pass	31	15	434,807	2,235	432,572	0
OpenCDISC SDTM v3.1.2 Controlled Terminology	89	Pass	31	4	100,159	10	100,157	2
Tool Support								
MAED	60	Pass	3	2	49,698	0	49,697	1
JMP Clinical	0	Fail	9	17	104,254	24	104,228	2

A Few Final Keynote Ideas for the Road



"I look to the future because that's where I'm going to spend the rest of my life.

George Burns

The World Wide Web project

info.cern.ch/hypertext/WWW/TheProject.html

GoToMeeting iGoogle Apple Yahoo! Google Maps YouTube Wikipedia News Popular Portal Sign In CDISC

Imagin... Beginne... Basic R... SDTM SDTMv... Yahoo! Home Pharma... The Wo... >> +

World Wide Web

The WorldWideWeb (W3) is a wide-area [hypermedia](#) information retrieval initiative aiming to give universal access to a large universe of documents.

Everything there is online about W3 is linked directly or indirectly to this document, including an [executive summary](#) of the project, [Mailing lists](#) , [Policy](#) , November's [W3 news](#) , [Frequently Asked Questions](#) .

[What's out there?](#)
Pointers to the world's online information, [subjects](#) , [W3 servers](#), etc.

[Help](#)
on the browser you are using

[Software Products](#)
A list of W3 project components and their current state. (e.g. [Line Mode](#) ,X11 [Viola](#) , [NeXTStep](#) , [Servers](#) , [Tools](#) , [Mail robot](#) , [Library](#))

[Technical](#)
Details of protocols, formats, program internals etc

[Bibliography](#)
Paper documentation on W3 and references.

[People](#)
A list of some people involved in the project.


[History](#)
A summary of the history of the project.

[How can I help ?](#)
If you would like to support the web..

[Getting code](#)
Getting the code by [anonymous FTP](#) , etc.

Semantic Modeling

2. Content and Schema



Everything is a Triple

Source: Frederik Malfait

CDISC2RDF

ABOUT

About

A blog to present upcoming results from our explorative work making CDISC standards available in semantic web standards (RDF triple based) as proposed by early adopters in AstraZeneca and Roche, see [Semantic models for CDISC based standard and metadata management](#).

Share this: [Twitter](#) [Facebook](#) [LinkedIn](#) [Google +1](#) [Email](#)

Like this: [★ Like](#)

Be the first to like this.

AUTHOR



kerfors



Leave a Reply

Enter your comment here

Follow

Towards practical, high-capacity, low-maintenance information storage in synthesized DNA : Nature : Nature Publishing Group

www.nature.com/nature/journal/v494/n7435/full/nature11875.html

GoToMeeting iGoogle Apple Yahoo! Google Maps YouTube Wikipedia News Popular Portal Sign In CDISC

World P... iGoogle CDISC B... Yahoo! Home 5 Steps... Optimi... Toward... Pharma... Ben Gol... >> +

nature International weekly journal of science

Home News & Comment Research Careers & Jobs Current Issue Archive Audio & Video For Authors

Archive Volume 494 Issue 7435 Letters Article

ARTICLE PREVIEW
view full access options >

NATURE | LETTER

日本語要約

Towards practical, high-capacity, low-maintenance information storage in synthesized DNA

Nick Goldman, Paul Bertone, Siyuan Chen, Christophe Dessimoz, Emily M. LeProust, Botond Sipos & Ewan Birney

Affiliations | Contributions | Corresponding author

Nature 494, 77–80 (07 February 2013) | doi:10.1038/nature11875
Received 15 May 2012 | Accepted 12 December 2012 | Published online 23 January 2013

Citation Reprints Rights & permissions Metrics

Digital production, transmission and storage have revolutionized how we access and use information but have also made archiving an increasingly complex task that requires active, continuing maintenance of digital media. This challenge has focused some interest on DNA as an attractive target for information storage¹ because of its capacity for high-density information encoding, longevity under easily achieved conditions^{2,3,4} and proven track record as an information bearer. Previous DNA-based information storage approaches have encoded only trivial amounts of information^{5,6,7} or were not amenable to scaling-up⁸, and used no robust error-correction and lacked examination of their cost-efficiency for large-scale information archival⁹. Here we describe a scalable method that can reliably store more information than has been handled before. We encoded computer files totalling 739 kilobytes of hard-disk storage and with an estimated Shannon information¹⁰ of 5.2×10^9 bits into a DNA code, synthesized this DNA, sequenced it and reconstructed the original files with 100% accuracy. Theoretical analysis indicates that our DNA-based storage scheme could be scaled far beyond current global information volumes and offers a realistic technology for large-scale, long-term and infrequently accessed

Journal home Subscribe
Current issue E-alert sign up
For authors RSS feed

Access Nature weekly, anytime, anywhere this Spring £60/\$60/€60

Selected feature



Celebrate the unknowns
On the 60th anniversary of the double helix, we should admit that we don't fully understand how evolution works at the molecular level, suggests Philip Ball.

See complete feature >

Editor's summary العربية

Long-term DNA archives make sense
This multidisciplinary study in synthetic biology both proposes and demonstrates a system for the DNA-based storage of digital information. Digital information is being produced at an ever-growing rat...

Science jobs from naturejobs

Tier 2 Canada Research Chair in Neuroscience / Brain Repair Assistant Professor
Memorial University of Newfoundland



Strength *through collaboration.*

"If I could drop dead right now, I'd be the happiest man alive."

-- Samuel Goldwyn

"Ask not what you can do for your country, ask what's for lunch."

-- Orson Welles